NCT03279692 2026-01-29Phase II Trial of Pembrolizumab in Recurrent or Residual High Grade MeningiomaMassachusetts General HospitalPhase 2 Active not recruiting26 enrolled 14 charts
NCT02648997 2026-01-26An Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants With Progessive/ Recurrent MeningiomaDana-Farber Cancer InstitutePhase 2 Active not recruiting40 enrolled 14 charts